Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
Status:
Not yet recruiting
Trial end date:
2032-10-01
Target enrollment:
Participant gender:
Summary
This is a single center, open-label phase I clinical trial designed to determine the safety
of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently
with pembrolizumab in subjects with advanced squamous non-small cell lung cancer (NSCLC) or
squamous cell carcinoma of head and neck (SCCHN).